Dapagliflozin for graft vs host disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Oct 2024: Trial registered, NCT06626737
  2. 26 Apr 2025: Trial started, NCT06626737

The trials

NCT06626737: Dapagliflozin in Allo-HCT for aGVHD

State
Under way
Phase
Phase 2
People
72 planned
Started
26 Apr 2025
Primary completion
31 Dec 2025
Arms
Dapagliflozin arm
Results
None posted
  1. 4 Oct 2024: Trial registered
  2. 26 Apr 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Dapagliflozin component qternmet, Dapagliflozin (DAPA), Dapagliflozin 10 MG, Dapagliflozin 10 mg daily, Qternmet xr component dapagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.